Expect Q1 2024 product launch Nitisinone market estimated to be more than $50 million annually Eton will offer Eton Cares support program to all patients DEER PARK, Ill., Oct. 04,.
Eton Pharmaceuticals (ETON) Acquires FDA-Approved Ultra-Rare Disease Product Nitisinone streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Toxoplasmosis is an infection caused by common parasite, which is found in cat feces and in contaminated food. This parasite is known as Toxoplasma gondii. The symptoms of toxoplasmosis disease include body aches and pain, headache, fatigue, fever, and swollen lymph nodes. In addition, people with weakened immune sy.
Second Quarter 2022 Results: Net revenues of $73.9 million, net loss available to common shareholders of $(15.3) million and diluted GAAP loss per share of $(0.94) – Lead Rare Disease asset, Purified Cortrophin® Gel (Repository Corticotrophin Injection USP) 80 U/ml (Cortrophin) net sales of $10.2 million Ad.
08.08.2022 - ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced business highlights and financial results for the three and six months ended June 30, 2022. “Second quarter net revenues of $73.9 million represent a new quarterly record .